212 related articles for article (PubMed ID: 30242647)
21. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
[TBL] [Abstract][Full Text] [Related]
22. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia.
Du S; Wang Z; Sang X; Lu X; Zheng Y; Xu H; Xu Y; Chi T; Zhao H; Wang W; Cui Q; Zhong S; Huang J; Mao Y
Medicine (Baltimore); 2015 Jan; 94(2):e388. PubMed ID: 25590842
[TBL] [Abstract][Full Text] [Related]
23. Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS).
Aoki T; Kubota K; Kiritani S; Arita J; Morizane C; Masui T; Kudo A; Komoto I; Hatano E; Ito T; Osamura RY; Unno M; Uemoto S; Kokudo N;
J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):489-497. PubMed ID: 33792204
[TBL] [Abstract][Full Text] [Related]
24. Transplant oncology: multivisceral transplantation for neuroendocrine tumor and liver metastasis.
Nagai S
Curr Opin Organ Transplant; 2023 Jun; 28(3):222-227. PubMed ID: 37040627
[TBL] [Abstract][Full Text] [Related]
25. Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.
Zaydfudim VM; Vachharajani N; Klintmalm GB; Jarnagin WR; Hemming AW; Doyle MB; Cavaness KM; Chapman WC; Nagorney DM
Ann Surg; 2016 Oct; 264(4):650-8. PubMed ID: 27433910
[TBL] [Abstract][Full Text] [Related]
26. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
[TBL] [Abstract][Full Text] [Related]
27. Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy.
Kiritani S; Arita J; Matsumura M; Nishioka Y; Kudo H; Ichida A; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
Surgery; 2020 Feb; 167(2):404-409. PubMed ID: 31635827
[TBL] [Abstract][Full Text] [Related]
28. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.
Mayo SC; de Jong MC; Pulitano C; Clary BM; Reddy SK; Gamblin TC; Celinksi SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Ferrero A; Schulick RD; Choti MA; Mentha G; Strub J; Bauer TW; Adams RB; Aldrighetti L; Capussotti L; Pawlik TM
Ann Surg Oncol; 2010 Dec; 17(12):3129-36. PubMed ID: 20585879
[TBL] [Abstract][Full Text] [Related]
29. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
[TBL] [Abstract][Full Text] [Related]
30. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
[TBL] [Abstract][Full Text] [Related]
31. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
[TBL] [Abstract][Full Text] [Related]
32. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons.
Sposito C; Droz Dit Busset M; Citterio D; Bongini M; Mazzaferro V
Rev Endocr Metab Disord; 2017 Dec; 18(4):473-483. PubMed ID: 29359266
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
34. Treatment of liver metastases in patients with neuroendocrine tumors.
Frilling A; Rogiers X; Malagó M; Liedke OM; Kaun M; Broelsch CE
Langenbecks Arch Surg; 1998 Mar; 383(1):62-70. PubMed ID: 9627173
[TBL] [Abstract][Full Text] [Related]
35. Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis.
Sahara K; Merath K; Tsilimigras DI; Hyer JM; Guglielmi A; Aldrighetti L; Weiss M; Fields RC; Poultsides GA; Maithel SK; Endo I; Pawlik TM; Other Members Of The U S Neuroendocrine Tumor Study Group
J Surg Oncol; 2019 Dec; 120(7):1087-1095. PubMed ID: 31550406
[TBL] [Abstract][Full Text] [Related]
36. The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.
Citterio D; Coppa J; Sposito C; Busset MDD; Virdis M; Pezzoli I; Mazzaferro V
Curr Treat Options Oncol; 2023 Nov; 24(11):1651-1665. PubMed ID: 37882889
[TBL] [Abstract][Full Text] [Related]
37. ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry.
Linecker M; Kambakamba P; Raptis DA; Malagó M; Ratti F; Aldrighetti L; Robles-Campos R; Lehwald-Tywuschik N; Knoefel WT; Balci D; Ardiles V; De Santibañes E; Truant S; Pruvot FR; Stavrou GA; Oldhafer KJ; Voskanyan S; Mahadevappa B; Kozyrin I; Low JK; Ferrri V; Vicente E; Prachalias A; Pizanias M; Clift AK; Petrowsky H; Clavien PA; Frilling A
HPB (Oxford); 2020 Apr; 22(4):537-544. PubMed ID: 31540885
[TBL] [Abstract][Full Text] [Related]
38. The timing of liver transplantation after primary hepatectomy for hepatocellular carcinoma: a special reference to recurrence pattern and Milan criteria.
Ikegami T; Shimada M; Imura S; Yoshizumi T; Arakawa Y; Tokunaga T; Morine Y; Kanemura H
Transplantation; 2008 Sep; 86(5):641-6. PubMed ID: 18791443
[TBL] [Abstract][Full Text] [Related]
39. [Factors for predicting outcomes of liver transplantation and liver resection for hepatocellular carcinoma meeting Milan criteria].
Huang J; Zhou J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Mar; 34(3):406-9. PubMed ID: 24670459
[TBL] [Abstract][Full Text] [Related]
40. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2020 Oct; 27(10):3717-3726. PubMed ID: 32436187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
